PDS Biotechnology Corporation Gains 60.32%

PDS Biotechnology Corporation (PDSB:NASDAQ) rocketted at $1.2, a gain of 60.3%. On Mon, Oct 05, 2026, PDSB:NASDAQ touched a New 2-Week High of $1.2. The stock got featured on our News Catalysts scanner on Sat, Oct 03, 2026 at 01:06 AM in the 'BIOTECH' category. From Mon, Sep 21, 2026, the stock recorded 40.00% Up Days and 36.36% Green Days

The stock spiked on Thu, May 14, 2026 at $1.55 with a volume of 2M+.

About PDS Biotechnology Corporation (PDSB:NASDAQ)

Edge Therapeutics Inc operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. Its core objective lies in the development and commercialization of therapies for serious unmet medical conditions, especially neurological disorders in the hospital setting. The company is currently evaluating EG-1962, its lead product candidate, in the Phase 3 NEWTON 2 study in adult patients with aneurysmal subarachnoid hemorrhage (aSAH). Edge uses its trademark platform known as Precisa, which enables the creation of polymer-based therapeutics capable of delivering directly to the site of injury, without affecting other areas of the body resulting in side-effects.